Orthocell (ASX:OCC) said 10 surgeries have taken place in the US using its nerve repair product, Remplir, and it lodged 36 applications to hospital value assessment committees with three approvals already received, according to a Wednesday Australian bourse filing.
The hospitals targeted for value assessment committee approval have been sourced from the firm's network of US distributors.
The company hired two on-the-ground employees in the US, including a regional sales director, per the filing. It also shipped 4,000 Remplir units to its US logistics provider, Uniphar, for use in US surgical procedures.
Orthocell's shares rose nearly 2% in early trading on Wednesday.